DexCom (NASDAQ:DXCM) Price Target Cut to $115.00

DexCom (NASDAQ:DXCM) had its price objective decreased by stock analysts at Royal Bank of Canada from $120.00 to $115.00 in a research note issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical device company’s stock. Royal Bank of Canada’s target price indicates a potential upside of 53.54% from the stock’s current price.

A number of other analysts also recently weighed in on the company. Morgan Stanley decreased their price target on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Friday, July 26th. Robert W. Baird upped their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Barclays lowered their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th. Finally, Stifel Nicolaus lifted their price target on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Seven equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $105.75.

DexCom Stock Performance

Shares of DexCom stock traded up $0.05 during trading hours on Friday, hitting $74.90. 9,605,399 shares of the company were exchanged, compared to its average volume of 3,881,020. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The business has a 50-day moving average of $70.13 and a 200-day moving average of $98.71. DexCom has a 1 year low of $62.34 and a 1 year high of $142.00. The stock has a market capitalization of $29.79 billion, a price-to-earnings ratio of 48.32, a P/E/G ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 24th. The medical device company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The company had revenue of $994.20 million during the quarter, compared to the consensus estimate of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. As a group, analysts expect that DexCom will post 1.69 EPS for the current fiscal year.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,824 shares of company stock valued at $126,390. 0.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DXCM. Crewe Advisors LLC bought a new position in shares of DexCom during the first quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the 2nd quarter worth approximately $25,000. Sachetta LLC increased its holdings in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares during the last quarter. DT Investment Partners LLC increased its holdings in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares during the last quarter. Finally, RiverPark Advisors LLC acquired a new stake in shares of DexCom during the 1st quarter valued at approximately $55,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.